AZD-7295
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- AZD-7295
- DrugBank Accession Number
- DB12724
- Background
AZD7295 has been investigated for the treatment of Hepatitis C.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 644.71
Monoisotopic: 644.228025906 - Chemical Formula
- C32H35F3N4O5S
- Synonyms
- Not Available
- External IDs
- AZD7295
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Benzanilides
- Alternative Parents
- Biphenyls and derivatives / Benzamides / Benzoyl derivatives / Benzylamines / N-arylamides / Phenol ethers / Phenoxy compounds / Phenylmethylamines / Aralkylamines / N-alkylpiperazines show 14 more
- Substituents
- 1,4-diazinane / Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzamide / Benzanilide show 34 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 102MC1467J
- CAS number
- 929890-64-2
- InChI Key
- MAQDQJWCSSCURR-UHFFFAOYSA-N
- InChI
- InChI=1S/C32H35F3N4O5S/c1-2-19-45(42,43)39-17-15-38(16-18-39)21-22-3-11-26(12-4-22)36-30(40)24-7-5-23(6-8-24)28-20-27(37-31(41)25-9-10-25)13-14-29(28)44-32(33,34)35/h3-8,11-14,20,25H,2,9-10,15-19,21H2,1H3,(H,36,40)(H,37,41)
- IUPAC Name
- 5'-cyclopropaneamido-N-(4-{[4-(propane-1-sulfonyl)piperazin-1-yl]methyl}phenyl)-2'-(trifluoromethoxy)-[1,1'-biphenyl]-4-carboxamide
- SMILES
- CCCS(=O)(=O)N1CCN(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C3=CC(NC(=O)C4CC4)=CC=C3OC(F)(F)F)C=C2)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 57339445
- PubChem Substance
- 347828919
- ChemSpider
- 34542361
- ZINC
- ZINC000095627833
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Healthy Volunteers (HV) 1 1 Completed Treatment Healthy Volunteers (HV) 2 1 Completed Treatment Hepatitis C Virus (HCV) Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.002 mg/mL ALOGPS logP 4.57 ALOGPS logP 5.7 Chemaxon logS -5.5 ALOGPS pKa (Strongest Acidic) 13.71 Chemaxon pKa (Strongest Basic) 6.05 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 108.05 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 163.92 m3·mol-1 Chemaxon Polarizability 65.94 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 246.50778 predictedDeepCCS 1.0 (2019) [M+H]+ 248.36009 predictedDeepCCS 1.0 (2019) [M+Na]+ 254.01125 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 23:50 / Updated at June 12, 2020 16:53